The US Food and Drug Administration (FDA) has approved a drug for heart failure manufactured by Texas-based Lexicon Pharma, it was reported on Saturday.

Sotagliflozin, an oral drug, is the company's first to be approved by the US health agency. It will be sold under the brand name Inpefa. An earlier drug from the firm, which is an add-on to insulin therapy for type 1 diabetes, had failed to get US approval.

The drug is aimed at a broad treatment of heart failure diseases, including in adult patients with type 2 diabetes.